Stock NVST ENVISTA HOLDINGS CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Financials Envista Holdings Corporation

Equities

NVST

US29415F1049

Medical Equipment, Supplies & Distribution

Market Closed - Nyse
Other stock markets
 04:00:02 2024-04-26 pm EDT 		5-day change 1st Jan Change
20.39 USD +1.85% Intraday chart for Envista Holdings Corporation +2.15% -15.25%
Apr. 26 Morgan Stanley Downgrades Envista Holdings to Equalweight From Overweight, Cuts Price Target to $21 From $33 MT
Apr. 15 Envista Holdings Names Paul Keel as CEO MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 4,702 5,385 7,271 5,490 4,124 3,504 - -
Enterprise Value (EV) 1 5,816 6,290 7,513 6,264 4,697 4,003 3,593 3,277
P/E ratio 18.5 x 169 x 23.5 x 24.6 x -40.1 x 18.2 x 16.8 x 14.9 x
Yield - - - - - - - -
Capitalization / Revenue 1.71 x 2.36 x 2.9 x 2.14 x 1.61 x 1.35 x 1.3 x 1.24 x
EV / Revenue 2.11 x 2.76 x 2.99 x 2.44 x 1.83 x 1.54 x 1.33 x 1.16 x
EV / EBITDA 13.8 x 20.8 x 15.2 x 12.1 x 10.1 x 9.36 x 7.65 x 6.48 x
EV / FCF 18.1 x 26.6 x 22.3 x 58.5 x 21.6 x 14.8 x 10.5 x 9.53 x
FCF Yield 5.52% 3.75% 4.48% 1.71% 4.63% 6.74% 9.53% 10.5%
Price to Book 1.33 x 1.45 x 1.79 x 1.31 x 0.99 x 0.79 x 0.75 x 0.71 x
Nbr of stocks (in thousands) 158,651 159,642 161,368 163,045 171,402 171,855 - -
Reference price 2 29.64 33.73 45.06 33.67 24.06 20.39 20.39 20.39
Announcement Date 1/30/20 2/10/21 2/9/22 2/8/23 2/7/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 2,752 2,282 2,509 2,569 2,566 2,600 2,703 2,835
EBITDA 1 420.7 303.1 495 517.4 464.2 427.5 469.8 506.1
EBIT 1 380.2 261.6 459.3 482.5 425.8 389.5 430.1 463.8
Operating Margin 13.82% 11.46% 18.31% 18.78% 16.59% 14.98% 15.92% 16.36%
Earnings before Tax (EBT) 1 275.5 -30.1 254.5 283.9 -54.9 281.1 316.6 -
Net income 1 217.6 33.3 340.5 243.1 -100.2 199.7 219.6 244.1
Net margin 7.91% 1.46% 13.57% 9.46% -3.9% 7.68% 8.13% 8.61%
EPS 2 1.600 0.2000 1.920 1.370 -0.6000 1.119 1.213 1.364
Free Cash Flow 1 321.3 236.2 336.7 107 217.5 269.9 342.5 344
FCF margin 11.68% 10.35% 13.42% 4.16% 8.47% 10.38% 12.67% 12.13%
FCF Conversion (EBITDA) 76.37% 77.93% 68.02% 20.68% 46.85% 63.13% 72.9% 67.97%
FCF Conversion (Net income) 147.66% 709.31% 98.88% 44.01% - 135.14% 155.94% 140.92%
Dividend per Share 2 - - - - - - - -
Announcement Date 1/30/20 2/10/21 2/9/22 2/8/23 2/7/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 607.3 651.8 631.4 645.8 631.1 660.8 627.2 662.4 631.3 645.6 634.5 658 642.5 666.9 658.2
EBITDA 1 119.1 120.7 124.6 126.9 127.6 138.3 114 126.2 123.5 100.5 98.07 107.4 108.2 116.7 110.8
EBIT 1 110.6 110.7 116.5 118.3 119.5 128.2 105.2 116.6 114.4 89.6 89.06 97.44 98.22 106.9 101.2
Operating Margin 18.21% 16.98% 18.45% 18.32% 18.94% 19.4% 16.77% 17.6% 18.12% 13.88% 14.04% 14.81% 15.29% 16.02% 15.38%
Earnings before Tax (EBT) 1 69.9 37.2 85.9 59.1 63.2 75.7 55.7 68.6 35.8 -215 58.88 69.75 71.08 81.35 68.23
Net income 1 92.9 85.8 74.9 44.5 47.6 73.5 43.8 51.9 21.5 -217.4 41.93 50.18 52.16 59.42 49.53
Net margin 15.3% 13.16% 11.86% 6.89% 7.54% 11.12% 6.98% 7.84% 3.41% -33.67% 6.61% 7.63% 8.12% 8.91% 7.53%
EPS 2 0.5200 0.4800 0.4200 0.2500 0.2700 0.4200 0.2500 0.2900 0.1200 -1.270 0.2348 0.2795 0.2843 0.3052 0.2798
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 11/3/21 2/9/22 5/4/22 8/3/22 11/3/22 2/8/23 5/3/23 8/2/23 11/1/23 2/7/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 1,114 906 242 774 573 499 89.2 -
Net Cash position 1 - - - - - - - 227
Leverage (Debt/EBITDA) 2.647 x 2.988 x 0.4893 x 1.496 x 1.235 x 1.167 x 0.1898 x -
Free Cash Flow 1 321 236 337 107 218 270 342 344
ROE (net income / shareholders' equity) 5.2% 4.44% 8.44% 8.36% 6.42% 5.31% 5.64% 6.57%
ROA (Net income/ Total Assets) 3.63% 0.51% 4.88% 5.25% 4.08% 3.83% 4.27% 4.9%
Assets 1 6,000 6,517 6,977 4,633 -2,455 5,209 5,147 4,982
Book Value Per Share 2 22.30 23.20 25.10 25.80 24.30 25.70 27.10 28.50
Cash Flow per Share 2 2.910 1.730 2.200 1.030 1.650 2.050 2.220 -
Capex 1 77.8 47.7 54.7 75.7 58.2 63.2 67.3 70.2
Capex / Sales 2.83% 2.09% 2.18% 2.95% 2.27% 2.43% 2.49% 2.47%
Announcement Date 1/30/20 2/10/21 2/9/22 2/8/23 2/7/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Envista Holdings Corporation

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
20.39 USD
Average target price
23.18 USD
Spread / Average Target
+13.69%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

1st Jan change Capi.
ENVISTA HOLDINGS CORPORATION Stock Envista Holdings Corporation
-15.25% 3.5B
ABBOTT LABORATORIES Stock Abbott Laboratories
-2.31% 187B
MEDTRONIC PLC Stock Medtronic plc
-3.20% 106B
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-5.04% 66.9B
DEXCOM, INC. Stock DexCom, Inc.
+0.20% 49.45B
CENCORA, INC. Stock Cencora, Inc.
+17.29% 48B
HOYA CORPORATION Stock Hoya Corporation
+4.06% 40.84B
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
+2.36% 26.25B
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+2.07% 26.48B
TERUMO CORPORATION Stock Terumo Corporation
+12.96% 24.62B
Other Medical Equipment, Supplies & Distribution
  1. Stock Market
  2. Equities
  3. NVST Stock
  4. Financials Envista Holdings Corporation